JAMA Current Issue

CNM-Au8 in Amyotrophic Lateral Sclerosis

This randomized, multicenter platform trial investigates the efficacy of CNM-Au8, an oral suspension of catalytically active gold particles, on the disease progression of patients with amyotrophic lateral sclerosis.

Apr 1, 2025 - 16:46
 0
This randomized, multicenter platform trial investigates the efficacy of CNM-Au8, an oral suspension of catalytically active gold particles, on the disease progression of patients with amyotrophic lateral sclerosis.
Read More

Tags:

Previous Article

Platform Clinical Trials for the Efficient Evaluation of Multiple Treatments

Next Article

Adjuvant Atezolizumab for Triple-Negative Breast Cancer

Related Posts

Textual Representation in Poetry—And at the End of Life

Feb 18, 2025  0

Falling Back

Apr 1, 2025  0

Incorrect Description of Adverse Childhood Experiences ...

Mar 18, 2025  0